Elagolix sodium was originally developed by Neurocrine Biosciences and later licensed worldwide to AbbVie. In November 2017, AbbVie submitted a marketing application to the U.S. Food and Drug Administration (FDA), which was approved by the FDA on July 23, 2018 under the trade name Orilissa.
Effect of Elagolix sodium
Elagolix sodium is an orally selective gonadotropin-releasing hormone (GnRH) receptor antagonist used primarily for the treatment of moderate to severe pain associated with endometriosis. It relieves pain by blocking the pituitary gland response to GnRH and lowering gonadotropin and sex hormone levels.
Indications and Targets
Elagolix sodium is indicated for pain management in patients with endometriosis, especially when conventional therapies are ineffective or cannot be tolerated. Its target is GnRHR, which can achieve effective pain control through precise intervention.
Clinical manifestations and efficacy
Clinical studies have shown that Elagolix can significantly improve the pain symptoms and improve the quality of life of patients. At the same time, it has a good safety profile, and although there are some adverse reactions, it is generally controllable, providing patients with new treatment options.
With its unique efficacy and safety, Elagolix sodium occupies an important position in the treatment of endometriosis.
Dosage of sodium Elagolix
The dosage and dosage of sodium Elagolix need to be adjusted according to the specific situation of the patient to maintain the best efficacy and safety.
Dosing information and dose adjustments
Before starting to take Elagolix sodium, pregnancy should be excluded or it should be started within 7 days after menstruation. Take at about the same time every day, before and after meals. Use the lowest effective dose and consider the severity of symptoms and treatment goals. In patients with hepatic impairment, the dose should be adjusted according to the degree of impairment.
Missed doses and medication in special populations
If you miss a dose of Elagolix sodium, you should immediately make up the dose on the same day and resume the normal time of taking the drug. For pregnant and lactating women, pediatric patients, and elderly patients, it should be used with caution and adjust the dose under the guidance of a doctor. This drug should be contraindicated, especially in pregnant women.
Therefore, reasonable dosage is the key to stabilizing the efficacy and safety of Elagolix sodium.
Storage of Elagolix
Proper storage is important to maintain the stability of sodium Elagolix.
Storage conditions and expiration date
Elagolix sodium should be stored in an environment between 2°C and 30°C to avoid too high or too low a temperature that affects the quality of the drug. At the same time, it is necessary to pay attention to the expiration date of the drug and avoid using expired drugs.
Treat unused medications
For unused Elagolix, if there is a recycling channel, it should be disposed of by recycling, and should not be discarded or flushed into the toilet bowl at will to reduce environmental pollution.
Proper storage is not only about the efficacy and safety of medicines, but also about being environmentally responsible. By following the above storage recommendations, the sodium can remain stable and effective during the expiration date, providing patients with better treatment protection.
